Mineralys Therapeutics
Mineralys Therapeutics Inc is an American clinical-stage biopharmaceutical company focused on developing targeted therapies for hypertension and cardiorenal diseases. The company is developing its lead drug candidate, lorundrostat, an oral highly selective aldosterone synthase inhibitor designed to lower blood pressure in patients with uncontrolled or resistant hypertension. Revenue is currently driven primarily by research agreements, development partnerships, and capital raises ahead of commercial market authorization. Core end markets serve cardiology practices, nephrology clinics, hypertension treatment centers, and hospital systems globally. Mineralys Therapeutics occupies an innovative position in the biopharmaceutical sector through its targeted small molecule approaches to aldosterone-driven cardiovascular conditions. The company is headquartered in Radnor, Pennsylvania, and its common stock trades on the Nasdaq Global Select Market.
4 of the funds FundTelligence covers report a position in Mineralys Therapeutics.
- Legal name
- Mineralys Therapeutics Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 4
Funds holding Mineralys Therapeutics
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 0.88 % (full portfolio disclosed, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.09 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.01 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.01 % (full portfolio disclosed, September 2026)